Favorable Immune Checkpoint Inhibitor Outcome of Patients with Melanoma and NSCLC Harboring FAT1 Mutations

The authors investigated the association of FAT atypical cadherin 1 (FAT1) mutations with immune checkpoint inhibitor response and outcome.